New hope for Tough-to-Treat lung cancer patients

NCT ID NCT05297890

Summary

This study is testing whether the drug lorlatinib can help control advanced lung cancer that has a specific genetic change called ROS1 and has worsened despite two prior standard treatments. It involves 70 patients in China who have already tried crizotinib and platinum chemotherapy. Researchers will measure how well the tumor shrinks and how long the benefit lasts, while monitoring side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China

  • Chinese PLA Army Medical Center

    Chongqing, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • Guangdong Provincial People's hospital

    Guangzhou, Guangdong, 510080, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Henan Provincial People's Hospital

    Zhengzhou, China

  • Hunan Cancer Hospital

    Changsha, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, China

  • Shandong Cancer Hospital&Institute

    Jinan, China

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • Shanxi Cancer hospital

    Taiyuan, China

  • Sichuan Cancer Hospital & Institute

    Chengdu, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, China

  • Tangdu Hospital of The fourth Military Medical University Peoples Liberation Army of China

    Xi'an, China

  • The 1st Affiliated hospital of Wenzhou Medical University

    Wenzhou, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • The First Hospital of Jilin University

    Changchun, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China

  • The first Affiliated hospital, Sun Yat-Sen University

    Guangzhou, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • Xiamen Humanity Hospital

    Xiamen, China

  • Yunnan Cancer Hospital

    Kunming, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

Conditions

Explore the condition pages connected to this study.